Osteoporosis/ Osteopenia in RDEB- what's new?

4th Conference EB-CLINET Dr Anna Martinez September 27th 2017



Great Ormond Street **NHS** Hospital for Children

Outline

- Review of the literature
- Bone basics
- Risk factors for osteopenia in EB
- What's new
 - Retrospective study of children with RDEB at GOSH
 - Current status of bone health
- What's next

Current key literature bone health

- Francis Palisson group 2002
 - 7 children generalised EB
 - 3 had reduced BMD, low Vit D and severe limited mobility
- Anna Martinez group 2006
 - 39 children
 - All RDEB and JEB low BMD compared to matched controls
 - Correlation with inactivity not with Vit D

Current key literature bone health

- Anna Bruckner group 2011.
 - prospective study 24 children 2 centres
 - 20 RDEB had low aBMD
 - mobility was associated with low aBMD but not Vit D levels
- Tivoli in Milan 2017.
 - 20 children all 4 types of EB (10 RDEB)
 - Reported an association with Birmingham EB severity score & Vit D status with low BMD

3 chances to get our bone banked



Two Types of bone

- Cortical
 - dense outer part 80% weight of bone
- Trabecular bone
 - end of long bones
 - inside vertebral bodies
 - metabolically active bone









Vertebral Bodies





Bone remodelling cycle



Osteocytes

- Osteocytes make of 90% of the body's bone cells in connecting network
- This networks feed back mechanical strain to the osteoblasts & osteoclasts



Osteocytes

- Produce 2 essential cytokines
 - nuclear factor kappa B (NF-kB) ligand (RANKL)
 - macrophage colony-stimulating factor (M-CSF)
- Cytokines critical regulation osteoclast activity

Bone remodelling cycle



Bone strength dependent is on

- Mobility- bone loading
- Good nutrition- calcium and vit D
- Attainment of puberty
- Healthy and adequate numbers of bone cells



Pubertal delay in EB patients

Central delay as in other chronic inflammatory diseases

- Reduction GnRH
 - reduction FSH/LH



Puberty in EB patients

 Skeletal mass approximately doubles during puberty

Abnormal bone regulation

- Inflammation
 - activation of inflammatory cytokines
 - interleukins 1 & 6
 - TNF α
 - RANKL

Abnormal bone regulation

- Reduction mesenchymal stromal cells
 - Dr Tamai mentioned on Monday
 - Osteoblasts originate from these cells
 - This is likely to have impact on bone building potential in patients with EB

Bone remodelling cycle



Retrospective comparison of bone health in children with RDEB

- Jan 2000-Aug 2007
- 40 patients with RDEB aged
 7-8 and 15-18 years
- 20 in each group

Primary outcome measures

- vertebral fractures
- scoliosis
- pubertal delay
- lumbar spine aerial Bone Mineral Density (aBMD)
- age adjusted Z score (Z-score)

Lumbar areal Bone Mineral Density



Results 7-8 year old RDEB group 2007

- 36% had vertebral fractures
- 11% had scoliosis



Results 15-16 yr old RDEB group 2007

- 40% had vertebral fractures
- 30% had scoliosis
- 84% of these children had pubertal delay.



Pubertal delay definition

- Girls:
 - no breast development by 13 years in girl
 - no Menarche by 16 years
- Boys
 - testicular volume <4mls before 14 years





Results

 There was a highly significant decrease in BMD Z score (p<0.0001) with age

Abnormal BMD scores are not a fracture predictor



Vertebral compression fractures

 Surprisingly patients with fractures did not have significantly different BMD Z-scores from those without (P=ns, t-test).

Results

- Fractures present silently in vast majority cases
- Youngest child female age 5.75 years

Results in 2017 age 7-8 yrs.

- 6 children
 - 1 fracture

Age 8 girl

- 8 year old girl
- Fully mobile
- Normal biochemistry
- Presented July 2017 sudden onset back pain whilst in shower
- Last screen X-rays April 2017 normal

Age 8 girl

- Loss of 25% vertebral body height L2-L5
- Depression endplates
- Boxes collapsed

Results 15-16 yr old RDEB group 2017

- 3 children
 - no fractures
 - all reached puberty

Proposed screening & monitoring of bone health in RDEB

- Lateral spine X-ray annually from age 5 years
- DEXA
 - baseline age around puberty
 - before starting bisphosphonates
 - annually for monitoring treatment

Treatment of fractures

- Use bisphosphonates well tolerated
- Intravenous zoledronic acid
 - short infusion
 - 6 monthly
 - highly effective OI



We are making a difference

- In many ways
- Better overall care

How can we prevent fractures?

How can we prevent fractures?

- Optimize
 - nutrition
 - wound care
 - mobility



Pubertal attainment crucial

- Endocrinologist
- Psychologist











The future

- Good longitudinal studies of bone health
- Trials of non pharmacological interventions such as vibration platforms
- Pubertal attainment is critical to bank more bone mass and reduce fracture risk
- Consider new medicines for osteoporosis
 - Denosumab anti-RANKL

Acknowledgements

- Dr Moira Cheung
- All patients & team at GOSH

